Insmed to Present Pulmonary and Inflammatory Strategy at Two March Healthcare Conferences

Management to outline pulmonary and inflammatory strategy at two March conferences

Insmed Incorporated is presenting its clinical and commercial strategy at two major healthcare investor conferences in March, signaling a focused push to highlight its pulmonary and inflammatory medicines. Management is scheduled to speak at the 46th Annual TD Cowen Healthcare Conference in Boston on Monday, March 2, 2026 at 9:50 a.m. ET and at the Leerink Partners Global Healthcare Conference in Miami on Tuesday, March 10, 2026 at 8:00 a.m. ET. Both presentations are webcast live from Insmed’s investor relations site and archived for 30 days, enabling broader access to its program updates and corporate messaging.

The company uses the conference appearances to summarise progress across its approved therapies and mid‑ to late‑stage investigational portfolio for chronic, debilitating lung diseases and inflammatory conditions. Insmed emphasises its multipronged R&D approach that spans gene therapy, AI‑driven protein engineering, advanced protein manufacturing, RNA end‑joining and synthetic rescue technologies. Management frames the presentations around advancing “first‑ and best‑in‑class” therapies, commercial execution plans for its two approved respiratory treatments and continued investment in research collaborations that aim to accelerate development timelines.

Insmed positions the conference engagements as part of a broader effort to engage clinicians, partners and patient communities about its development priorities and patient‑centered care initiatives. The company underscores its commitment to sustained R&D funding and global collaborations as it moves programs through clinical milestones and seeks to broaden access to approved treatments. Webcast availability and archived replays also allow patients, healthcare professionals and potential partners to review the company’s scientific and commercial updates.

Pipeline breadth, employer recognition and global operations

Insmed describes a portfolio spanning approved therapies and early‑to‑late stage investigational programs focused on pulmonary and inflammatory disease areas. The company highlights a global footprint with offices and research locations across the United States, Europe and Japan, and notes recognition as a leading employer in the biopharmaceutical sector, including five consecutive years as the No. 1 Science Top Employer.

Webcast access and investor, media contacts

Insmed invites stakeholders to view live webcasts and 30‑day archived replays via the investor relations section of www.insmed.com and to follow corporate updates on LinkedIn, Instagram, YouTube and X. Media and investor inquiries are directed to Bryan Dunn, VP Investor Relations, and Claire Mulhearn, VP Corporate Communications, with contact details provided in the company release.